Synthetic Biologics Inc. is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of pertussis and Acinetobacter infections. In addition, Synthetic Biologics is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis.
The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
"What I like about this study is that it has an industry-standard primary endpoint, which is a two-year follow-up for relapsing-remitting MS patients. The last patient follow-up should occur in January 2014 and we should see the top-line results reported a few months later. If we get a good result, it's going to be a well-accepted because of the solid trial design. . .as the company moves forward, and with top-line results with Trimesta expected no later than mid-2014, I think we will see creation of value and potential licensing opportunities. Because of the trial design, with its well-established and accepted endpoint, positive data could open some doors for licensing."
Due to permission requirements, not all quotes are shown.
Synthetic Biologics Inc. Content
Back to Top